Fig. 14From: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluationMean body weight each week after tumour implantation of PC3 cells in disease and treatment (pure VC and VC-NFs) groups; n = 10, mean ± SD, p ≤ 0.05Back to article page